Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

903.02 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Of The Day: Is The Eli Lilly Selloff Over? ↗

March 18, 2026

Eli Lilly shares made a large move lower. But they are oversold and getting close to a level where there may be support.

Via Benzinga

Ardsley Dumps 440,000 Hut 8 Shares Worth $19.4 Million ↗

March 18, 2026

Hut 8 operates large-scale data centers supporting Bitcoin mining and high-performance computing for institutional clients.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

March 18, 2026

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot

March 18, 2026

As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year...

Via Finterra

Topics Intellectual Property

Members of Congress Bought These 5 Stocks—Should You? ↗

March 18, 2026

Via MarketBeat

Airlines Take Flight While Oil Burns: Markets Edge Higher Amid Middle East Tensions ↗

March 18, 2026

Via Chartmill

Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Zoetis (NYSE:ZTS)

March 17, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. Looking ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗

March 17, 2026

Each of these companies could benefit from this high-growth market over time.

Via The Motley Fool

Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗

March 17, 2026

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Via The Motley Fool

Topics Stocks

Stock Market Today, March 17: Markets Edge Upwards as Fed Meeting Opens ↗

March 17, 2026

Today, March 17, 2026, selective tech gains helped lift the Nasdaq even as oil prices and geopolitical tensions stayed elevated.

Via The Motley Fool

Topics Economy Stocks

Why Eli Lilly (LLY) Shares Are Plunging Today

March 17, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stoc...

Via StockStory

Worried the AI Hype Won't Last? These Dividend Stocks Offer Safer Exposure ↗

March 17, 2026

You don't have to go all in to profit from AI.

Via The Motley Fool

Topics Artificial Intelligence

Which S&P500 stocks are moving on Tuesday? ↗

March 17, 2026

Via Chartmill

LLY Shares Dive On Analyst Downgrade Citing Obesity Market Overestimation Concerns, But Retail Dismisses ‘Absurd’ Selloff ↗

March 17, 2026

The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.

Via Stocktwits

Tuesday's session: top gainers and losers in the S&P500 index ↗

March 17, 2026

Via Chartmill

Why Eli Lilly Stock Just Dropped ↗

March 17, 2026

Eli Lilly's stock price is based on growth rates that might fall short.

Via The Motley Fool

Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations ↗

March 17, 2026

HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations.

Via Benzinga

Tuesday's session: gap up and gap down stock in the S&P500 index ↗

March 17, 2026

Via Chartmill

This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock ↗

March 17, 2026

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Via The Motley Fool

Should You Avoid Pfizer? Here's the Key Risk to Watch ↗

March 17, 2026

Pfizer has reached a turning point.

Via The Motley Fool

Topics Intellectual Property

Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? ↗

March 16, 2026

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Via The Motley Fool

Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026

March 16, 2026

Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗

March 16, 2026

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Via The Motley Fool

Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial ↗

March 16, 2026

Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.

Via Benzinga

3 Companies at the Forefront of the GLP-1 Pill Wars ↗

March 16, 2026

Via MarketBeat

3 Quality Compounders to Own for Decades

March 16, 2026

Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr...

Via StockStory

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗

March 15, 2026

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

Via The Motley Fool

This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗

March 15, 2026

RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.

Via The Motley Fool

3 Stocks That Could Be Next to Announce a Stock Split ↗

March 15, 2026

Via MarketBeat

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand ↗

March 15, 2026

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.